@article{c794010d019b4dd1ace0975b7668b648,
title = "P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab",
author = "J. Rothenstein and A. Spira and V. Velcheti and R. Natale and M. Kozloff and M. Kosty and J. Goldschmidt and J. Mazieres and Aix, \{S. Ponce\} and W. Yu and M. Gandhi and A. Lee and G. Shankar and W. Lin and C. Thomas",
note = "In the randomized Phase III IMpower150 study, atezolizumab (anti-programmed death-ligand 1 [PD-L1]) + bevacizumab + chemotherapy (Arm B) showed statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) over bevacizumab + chemotherapy (Arm C) in patients with first-line (1L) nonsquamous non-small cell lung cancer (NSCLC).",
year = "2018",
month = oct,
day = "1",
doi = "10.1016/J.JTHO.2018.08.639",
language = "American English",
volume = "13",
journal = "Journal of Thoracic Oncology",
number = "10",
}